Combination chemotherapy preceding surgery in osteogenic sarcoma.
In 19 unselected subsequently entered non-metastatic patients with a normal osteogenic sarcoma two different just tolerable chemotherapy combinations were applied pre- and postoperatively. The median follow-up time after discontinuation of chemotherapy is 26+ months. Nine patients have failed, all showing pulmonary metastases, six have died despite several heavy salvage regimens. So the disease free survival rate is 53%. Longer follow-up in this group and the European Osteosarcoma Intergroup Study will be needed to clarify the value of neoadjuvant chemotherapy in this disease.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery